RNS Number : 1343W

Citadel Group

13 April 2023

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.             KEY INFORMATION

(a)   Full name of discloser	Citadel Group
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree	HORIZON THERAPEUTICS PLC
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)	N/A
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure	12 April 2023
(f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

2.             INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security (Note 3)	Common Stock ISIN IE00BQPVQZ61
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled	3,742,476	1.63	397	0.00
(2)   Cash-settled derivatives	0	0.00	0	0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell	100,000	0.04	50,000	0.02
Total	3,842,476	1.68	50,397	0.02

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)           Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit (Note 5)
Common	Buy Transaction	100	109.8200 USD
Common	Buy Transaction	200	109.8925 USD
Common	Buy Transaction	501	109.9368 USD
Common	Buy Transaction	100	109.9500 USD
Common	Buy Transaction	12,994	109.9752 USD
Common	Buy Transaction	52,030	110.2488 USD
Common	DVP Transaction	5,174	109.6800 USD
Common	RVP Transaction	5,174	109.6800 USD
Common	Sell Transaction	100	109.6700 USD
Common	Sell Transaction	10,301	109.6800 USD
Common	Sell Transaction	22	109.7573 USD
Common	Sell Transaction	1,028	109.7840 USD
Common	Sell Transaction	411	109.7846 USD
Common	Sell Transaction	202	109.7861 USD
Common	Sell Transaction	123	109.8469 USD
Common	Sell Transaction	20,000	109.8500 USD
Common	Sell Transaction	102	109.8767 USD
Common	Sell Transaction	253	109.8769 USD
Common	Sell Transaction	52	109.8785 USD
Common	Sell Transaction	349	109.9086 USD
Common	Sell Transaction	3	109.9100 USD
Common	Sell Transaction	200	109.9150 USD
Common	Sell Transaction	3,239	109.9234 USD
Common	Sell Transaction	1,314	109.9236 USD
Common	Sell Transaction	676	109.9236 USD
Common	Sell Transaction	22	109.9248 USD
Common	Sell Transaction	31	109.9252 USD
Common	Sell Transaction	218	109.9271 USD
Common	Sell Transaction	1,113	109.9273 USD
Common	Sell Transaction	447	109.9273 USD
Common	Sell Transaction	45	109.9302 USD
Common	Sell Transaction	410	109.9304 USD
Common	Sell Transaction	2,028	109.9316 USD
Common	Sell Transaction	821	109.9316 USD
Common	Sell Transaction	232	109.9325 USD
Common	Sell Transaction	210	109.9550 USD
Common	Sell Transaction	752	109.9551 USD
Common	Sell Transaction	50	109.9600 USD
Common	Sell Transaction	100	109.9611 USD
Common	Sell Transaction	243	109.9633 USD
Common	Sell Transaction	5	109.9700 USD
Common	Sell Transaction	10,000	110.0000 USD
Common	Sell Transaction	14	110.0182 USD
Common	Sell Transaction	19	110.0332 USD
Common	Sell Transaction	77	110.0565 USD
Common	Sell Transaction	150	110.0571 USD
Common	Sell Transaction	38	110.0614 USD
Common	Sell Transaction	372	110.0618 USD
Common	Sell Transaction	18	110.1500 USD
Common	Sell Transaction	7	110.1900 USD

Ap29

(b)           Cash-settled derivative transactions

Class of
relevant
security Product
description
e.g. CFD Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position Number of
reference
securities
(Note 6) Price
per unit
(Note 5)

(c)           Stock-settled derivative transactions (including options)

(i)            Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates (Note 6)	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
Common	Put Option	Buy Transaction	500	80.0000 USD	American	2023-Aug-18	1.0000 USD
Common	Call Option	Buy Transaction	500	115.0000 USD	American	2023-Aug-18	1.1000 USD
Common	Put Option	Sell Transaction	500	100.0000 USD	American	2023-Aug-18	3.1000 USD

(ii)           Exercise

Class of
relevant
security Product
description
e.g. call
option Exercising/
exercised
against Number of
securities Exercise
price per
unit
(Note 5)

(d)           Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security Nature of dealing
e.g. subscription,
conversion, exercise Details Price per unit (if
applicable)
(Note 5)

Ap30

4.             OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 None

(b)           Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 None

(c)           Attachments

Is a Supplemental Form 8 attached? YES

Date of disclosure	13 April 2023
Contact name	Paula Sharp
Telephone number	020 7645 9700

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1.             KEY INFORMATION

Full name of person making disclosure:	Citadel Group
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	HORIZON THERAPEUTICS PLC

2.             STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
Common	Put Option	Sold	50,000	100 USD	American	18/08/2023
Common	Call Option	Purchased	50,000	115 USD	American	18/08/2023
Common	Put Option	Purchased	- 50,000	80 USD	American	18/08/2023

3.             AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4.             RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEGPUUWCUPWUBW